检测卵巢上皮性肿瘤患者血清和肿瘤组织中VEGF的临床意义

背景及目的:本研究拟通过对卵巢上皮性肿瘤患者血清血管内皮生长因子(vascularepithelialgrowthfactor,VEGF)水平的检测及对卵巢上皮性肿瘤组织中VEGF表达的观察,以探讨VEGF与卵巢上皮性肿瘤临床、病理诸因素的关系。方法:卵巢上皮性肿瘤患者73例,其中24例为良性肿瘤患者(良性组),7例为交界性上皮瘤患者(交界性组),42例为恶性肿瘤患者(恶性组);以同期在本科室查体无明显妇科疾患的20名妇女血清做对照。用免疫组化二步法检测73例卵巢上皮性肿瘤患者肿瘤组织中VEGF的表达,用ELISA法测定71例卵巢上皮性肿瘤患者术前血清及10例患者腹水中VEGF水平,对其中7例卵巢上皮性癌患者血清在术后进行了定期检测。结果:①VEGF在卵巢上皮性肿瘤组织中的表达,恶性组阳性表达率(86.36%)明显高于交界性组(66.67%,P<0.005)及良性组(37.50%,P<0.005)。②良性组、交界性组及恶性组之间血清VEGF水平的差异有统计学意义(P<0.01);在恶性组中,血清VEGF水平在临床Ⅲ、Ⅳ期明显高于Ⅰ、Ⅱ期(P<0.05),在病理分化差的G3组明显高于病理分化好的G1、G2组(P<0.01),而与病理类型相关性无统计学意义;卵巢癌患者经理想的肿瘤细胞减灭术后,血清VEGF水平均有不同程度下降,有3例患者病情复发后,血清VEGF水平再度上升。结论:①VEGF在卵巢上皮性肿     

恶性肿瘤患者血清VEGF的检测及临床意义

目的评价血清VEGF在恶性肿瘤患者治疗中的临床价值。方法对337例未经治疗的恶性肿瘤患者、25例术后及22例术后复发的恶性肿瘤患者应用ELISA法进行了血清VEGF含量及阳性率检测,并以47例良性肿瘤及61例健康成人作为对照组。结果恶性肿瘤患者血清VEGF含量及阳性率明显高于健康对照组及良性肿瘤组(P<0.001),宫颈癌患者术后7￣10d较术前明显增高(P<0.02),术后1￣2个月恶性肿瘤患者较术前明显下降(P<0.001),而术后复发者又显著上升(P>0.05)。结论监测恶性肿瘤患者血清VEGF的动态变化有助于了解患者病情的发展。     

Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma

BACKGROUND: Vascular endothelial growth factor (VEGF) and VEGF-C play a crucial role in the regulation of tumor growth and metastasis. The current study examined the significance of serum VEGF and VEGF-C levels in relation to conventional clinicopathologic parameters, response to treatment, and survival in patients with cervical carcinoma. METHODS: Between December 1999 and March 2004, serum VEGF and VEGF-C levels were analyzed in 78 patients with cervical carcinoma undergoing primary treatment (primary surgery [n=40] and radiotherapy [n=38]), as well as in 30 healthy controls. Serum VEGF and VEGF-C levels were assessed by enzyme-linked immunosorbent assay before and within 2 weeks after treatment. RESULTS: Serum VEGF and VEGF-C levels were higher in patients with cervical carcinoma than in the healthy control (P=0.0002 and P=0.0007, respectively). Both VEGF and VEGF-C concentrations increased significantly in patients with squamous cell carcinoma (SCC vs. normal control: P<0.0001 and P=0.0001, respectively), but not in adenocarcinoma (vs. normal control: P=0.2982 and P=0.7766, respectively). In an analysis of SCC, the pretherapeutic serum levels of VEGF and VEGF-C correlated significantly with advanced International Federation of Gynecology and Obstetrics stage and large tumor size, but not with lymph node metastasis. The pretherapeutic serum level of VEGF-C also correlated significantly with disease recurrence or persistence after treatment. Both serum VEGF and VEGF-C levels decreased significantly after treatment. CONCLUSIONS: The serum levels of both VEGF and VEGF-C have potential usefulness as biologic markers of SCC of the uterine cervix.     

EBV DNA定量分析在监测鼻咽癌转移和复发中的临床意义

背景与目的:EB病毒(Epstein-Barrvirus,EBV)感染与鼻咽癌关系密切,近年来,有报道鼻咽癌患者血浆/血清中可检测到游离EBVDNA,但血浆EBVDNA水平对判断放疗后鼻咽癌患者转移、复发的临床意义尚缺少大宗研究报道。本研究定量检测鼻咽癌放疗后随诊患者血浆EBVDNA含量,探讨其在监测鼻咽癌转移、复发中的临床意义。方法:选择在中山大学肿瘤防治中心门诊随诊的放疗后鼻咽癌患者90例,用荧光定量PCR方法检测血浆EBVDNA含量,比较转移、复发与持续缓解患者血浆EBVDNA拷贝数。结果:放疗后转移或复发患者血浆EBVDNA的检出率为96.7%(29/30),中位拷贝数为2650copies/ml(0～5900000copies/ml);而持续缓解组患者血浆EBVDNA检出率12%(7/60),中位拷贝数为0copy/ml(0～71000copies/ml),差异均有统计学意义(P<0.01)。3例临床持续缓解但有血浆EBVDNA升高患者,在随后的3～4个月随访中,证实有肿瘤转移或复发。结论:血浆EBVDNA李宇红,等.EBVDNA定量分析在646定量检测可能成为监测放疗后鼻咽癌患者肿瘤转移、复发的敏感肿瘤标记物。     

食管鳞癌患者血清VEGF和一氧化氮含量测定及临床意义

背景与目的：肿瘤血管生成是肿瘤赖以生长和转移的基础,而血管内皮生长因子（vascular endothelial growth factor,VEGF)和一氧化氮（nitric oxide,NO)与血管新生密切相关,本实验旨在通过检测食管鳞癌患者血清中VEGF和NO的表达变化,分析其临床意义,为食管鳞癌病情判定及预后估计提供辅助手段。方法：分别采用酶联免疫吸附反应9enzyme-linked immunosorbant assay,ELISA)法和分光光度法检测50例食管鳞癌患者血清中VEGF和NO的含量,并分析其临床意义。结果：正常健康人血清中VEGF和NO含量与食管良性病变患者无显著差异（P＞0．05）;食管鳞癌患者血清VEGF和NO含量较健康人明显升高（P＜0．01）,且随着食管癌的分期、分级和淋巴结转移而显著增高（P＜0．01）,血清VEGF和NO含量呈正相关（P＜0．01）。结论：食管鳞癌患者血清中VEGF和NO表达的增高与肿瘤的发生、发展及恶性行为有关,可作为临床上判断预后的指标之一。     

常见消化道恶性肿瘤患者血清VEGF表达水平及其临床意义

目的研究血管内皮生长因子在常见恶性消化道肿瘤患者血清中的水平及其临床意义.方法应用酶联免疫吸附法(ELISA)检测210例恶性消化道肿瘤患者及87例对照者血清中血管内皮生长因子(vascular endothelial growth factor,VEGF)水平.结果肿瘤患者血清VEGF平均水平为201 ng/L,对照组为76.21 ng/L,两组差别有统计学意义(P＜0.001);有负荷组患者血清VEGF水平高于无负荷组(P＜0.001).血清VEGF水平与肿瘤分化程度、浸润深度和临床分期密切相关(P＜0.01),但与患者年龄、性别无关(P＞0.05).肿瘤患者血清VEGF水平随着KPS评分的降低,而逐渐升高(P＜0.05).结论VEGF作为一个促进血管渗透性和促进血管内皮生长的主要因子,在肿瘤发生、生长和转移过程中起着极其重要的作用,并可作为判断恶性肿瘤患者术后有无复发或转移的良好指标,在临床上具有重要的参考价值.     

直肠癌微血管密度与转移、复发的关系

背景与目的:肿瘤组织微血管密度(microvesseldensity,MVD)可部分地反映肿瘤血管生成的情况,是近年肿瘤研究领域的研究热点之一,目前MVD与直肠癌临床病理指标的关系尚存在分歧,本研究探讨直肠癌肿瘤组织MVD与转移、复发的关系。方法:收集1996～1997年本科手术切除的直肠癌患者97例的资料,并对其石蜡包埋的手术标本癌组织及75例癌旁非癌组织,以小鼠抗人CD31抗体经免疫组化LSAB法显示肿瘤组织和癌旁非癌组织的微血管,镜下测定MVD,并用统计软件包SPSS9.0分析MVD与直肠癌各临床病理指标的关系。结果:直肠癌肿瘤组织和癌旁非癌组织MVD测定结果分别为45.26±19.52和11.82±3.48每高倍视野(×400)(P<0.001),肿瘤组织MVD高于癌旁非癌组织MVD;术后转移、复发组和无转移、无复发组的MVD分别为62.72±21.75和41.23±16.68,两组差异有显著性(P<0.001)。结论:直肠癌肿瘤组织MVD高者术后易发生转移、复发,肿瘤组织MVD可作为直肠癌术后转移、复发的指标之一。     

Correlation of the Appearances of DSA with VEGF Expression and Its Clinical Significance in Patients with Primary Hepatocellular Carcinoma

目的探讨原发性肝癌患者的数字减影血管造影(DSA)表现和血管内皮细胞生长因子(VEGF)水平之间的关系。方法对24例原发性肝癌患者30次进行DSA的同时选用酶联免疫吸附定量法检测血清的VEGF水平。结果24例HCC血管造影中,18例有肝动脉肿瘤染色,瘤区肝动脉染色15例为多血供,3例为少血供;4例仅表现为门静脉供血; 1例为肠系膜上动脉供血,且合并大量门静脉瘘;另1例肿瘤无血供,HCC组血清VEGF表达水平(194．5±14．2)ng/L与对照组(132．4±47．9)比较,有显著性差异(P<0．01)。结论肝癌病灶血供丰富或伴有动静脉瘘形成者,血循环中VEGF浓度明显增高,且和肝内播散、肝癌复发及转移呈正相关。     

Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma

Objective: To explore serum angiogenic factor expression in patients with osteosarcoma and its relationshipwith metastasis. Methods: Immunohistochemistry was used to test the expression of CD34 and FⅧ-Rag inosteosarcoma tissues of 36 patients (osteosarcoma group) and microvessel density (MVD) was also recorded.In addition, ELISA was used to test the level of vascular endothelial growth factor (VEGF), basic fibroblastgrowth factor (bFGF), transforming growth factor-β1 (TGF-β1) and endostatin (ES) in the osteosarcoma groupand in a control group. Results: VEGF and ES level were significantly higher than in the control group beforeoperation (P<0.01), VEGF, bFGF and TGF-β1 correlating with the ES level (P<0.01). Serum VEGF and ESlevels of osteosarcoma patients before surgery were closely related to relapse and metastasis; moreover, serumVEGF increased with MVD (P<0.01). Postoperative VEGF and ES levels were lower than the preoperationvalues (P<0.01); ES level in relapse group was significantly higher than that of the non-relapse group (P<0.01).Conclusion: Preoperative serum VEGF and postoperative ES levels have great predictive value with regard torelapse of osteosarcoma patients.     

血管内皮生长因子在恶性肿瘤患者表达的临床研究

目的通过测定血管内皮生长因子(VEGF)在肿瘤患者血清及恶性渗出液中的含量,以明确VEGF能否作为肿瘤标志物。方法通过酶联免疫吸附法测定VEGF在健康人、肿瘤患者血清及恶性渗出液中的含量。结果恶性肿瘤患者血清中VEGF含量较健康组高,且有显著差异(P<0．01),但多数肿瘤转移与非转移组比较无差异(肝癌患者除外),非转移性胃肠道肿瘤患者血清中VEGF与CEA、CA19-9有相关性,其他恶性肿瘤血清中VEGF与CEA、CA19-9均无相关性。22例肺癌患者渗出液中VEGF中位数229．2pg/ml,比其血清中VEGF中位数高(62．2pg/ml)。有恶性渗出液患者血清中VEGF与其渗出液中VEGF无相关性,渗出液中VEGF与其CEA、CA19- 9及LDH亦无相关性。肺癌患者经治疗血清中VEGF随病情好转而下降,也可随病情进展而升高。结论①恶性肿瘤患者血清中VEGF水平比健康人高。②VEGF可作为一个非特异性的肿瘤标志物,且与治疗疗效呈正相关。     

IL-6与VEGF在食管鳞状细胞癌中的表达及其临床意义

目的：检测食管鳞状细胞癌（esophageal squamous cell cancer,ESCC）患者血清中白细胞介素-6（interleukin-6,IL-6）和ESCC组织中血管内皮生长因子（vascular endothelial growth factor,VEGF）的表达及其两者关系,并研究两者表达对ESCC的临床意义。方法：收集河北医科大学第四医院胸外科于2014年1月至2015年1月期间行ESCC切除术的患者52例,每例患者均取原发灶组织和癌旁组织标本;同时在术前抽取患者外周血5 ml,再取52例健康体检者外周血5 ml为血清对照。应用ELISA法测定ESCC患者血清中IL-6的水平,免疫组化技术检测VEGF在ESCC组织中的表达,RT-PCR法检测肿瘤组织中IL-6和VEGF mRNA的表达情况。结果：ESCC患者血清IL-6表达水平为（116.71±25.98）pg/ml,明显高于健康对照组的\[（78.43±9.36）pg/ml\]（P＜0.05）,血清中IL-6的表达水平与患者肿瘤分化程度、TNM分期、肿瘤浸润深度和淋巴结转移相关（P＜0.05）。肿瘤组织VEGF蛋白阳性表达率明显高于癌旁组织（67.31% vs 32.69%,P<0.01),且与患者肿瘤分化程度、TNM分期、肿瘤浸润深度和淋巴结转移相关（P＜0.05）。肿瘤组织中IL-6 mRNA的表达与VEGF mRNA的表达呈显著正相关（r=7.113,P＜0.05）。结论：ESCC患者肿瘤组织中IL-6和VEGF均呈高表达且两者呈正相关,两者可能在ESCC侵袭和转移中发挥重要作用。     

非小细胞肺癌组织成纤维细胞P-gp的表达及意义

目的:研究非小细胞肺癌组织中成纤维细胞P-gp的表达与临床病理特征的关系,探讨其对患者术后早期复发或远处转移的影响。方法:应用Max VisionTM快捷免疫组化检测48例非小细胞肺癌组织和10例非癌肺组织中成纤维细胞P-gp的表达,随访患者并研究其表达水平与术后早期复发的相关性。结果:非小细胞肺癌组织中成纤维细胞P-gp的表达阳性率为70.8%,明显高于非癌肺组织(P<0.01);成纤维细胞P-gp的表达与患者年龄、肿瘤分化程度、临床分期和有无淋巴结转移有关(P<0.05);与患者性别、大小和肿瘤组织类型无关(P>0.05),P-gp阳性患者术后1年内复发或远处转移率明显高于P-gp阴性患者。结论:P-gp参与了肿瘤细胞的耐药性的形成,肿瘤组织成纤维细胞P-gp的表达水平在患者术后早期复发及远处转移中具有重要意义。     

非小细胞肺癌患者血清VEGF表达水平及其临床意义

目的：检测非小细胞肺癌（NSCLC）患者血清血管内皮生长因子（vascula rendothelial growth factor,VEGF）的表达水平,探讨其临床意义。方法：应用酶联免疫吸附法（ELISA）检测114例NSCLC和87例健康对照组血清中VEGF水平,计算VEGF的灵敏度和特异度,阳性预测值和阴性预测值,分析患者治疗前血清VEGF水平对其近期疗效的影响以及VEGF与CYFRA21-1和CEA联合检测的临床意义。结果：（1）NSCLC组血清VEGF平均水平为203.70ng/L,对照组为76.21ng/L,两组差别有统计学意义（P〈0.001）。有负荷组患者血清VEGF水平高于无负荷组（P〈0.001）。（2）VEGF以200.6ng/L为医学参考值上限,VEGF对NSCLC诊断的灵敏度为69.7%,特异度为96.4%;有负荷组患者灵敏度可达到81.9%,而无负荷组仅为33.7%,其差别有统计学意义（P〈0.01）。（3）NSCLC患者随着血清VEGF平均水平的升高,其疗效逐渐降低（P〈0.05）。3种肿瘤标记物联合分析显示,随着患者血清肿瘤标记物阳性数目的增多,无效患者的比例呈上升趋势,当患者血清肿瘤标记物阳性数目达到3种时,约87.5%的患者治疗无效。（4）血清VEGF水平与肿瘤大小、分化程度及临床分期密切相关（P〈0.01）,与患者的年龄无关（P〉0.05）。结论：VEGF在NSCLC的发生、生长和转移过程中起着极其重要的作用,有可能成为一种新的肿瘤标记物用于NSCLC的辅助诊断或检测指标。     

肺癌患者血清VEGF含量检测的临床意义

目的　探讨肺癌患者血清血管内皮生长因子 (VEGF)含量变化的意义及其影响肺癌生长及转移的作用机制。方法原发性支气管肺癌 63例 ,采用免疫组化染色检测肺癌组织VEGF表达情况 ,酶联免疫吸附试验 (ELISA)测定血清VEGF含量 ,采用Kaplan Meier方法比较不同血清VEGF含量者的生存情况。 结果　肺癌患者血清VEGF含量明显高于正常对照组 ,不同性别、年龄、组织学类型、分化程度及T分期 (肿瘤原发状态 )血清VEGF含量无显著性差异 ,不同N分期 (淋巴结转移 )及临床分期间血清VEGF含量有显著性差异。肺癌患者血清VEGF含量与肺癌组织VEGF表达呈正相关。血清VEGF高含量患者生存时间明显短于血清VEGF低含量者。结论　血清VEGF与肺癌淋巴结转移及临床分期进展密切相关 ,血清VEGF含量可作为判断肺癌淋巴结转移潜能及预后评价的可靠参考指标。肺癌细胞分泌VEGF进入血液循环 ,从而促进肺癌的生长及转移     

晚期非小细胞肺癌患者化疗前后血清HIF-1α和VEGF的变化及临床意义

目的:探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者化疗前后外周血清缺氧诱导因子-1α（hypoxia inducible factor-1,HIF-1α）、血管内皮生长因子（vascular endothelial growth factor,VEGF）与化疗疗效之间的关系。方法:选择本院收治的22例NSCLC患者,采用酶联免疫吸附试验法(enzyme linked immunossorbent assay,ELISA)检测患者化疗前后血清中HIF-1α和VEGF的含量。结果:本组患者化疗总有效率为27%。化疗后患者血清HIF-1α和VEGF与化疗前比均有升高趋势,化疗无效组血清VEGF由（562.03±279.10）pg/ml升高为（740.26±364.34）pg/ml,差异显著（P＜0.05）。化疗前血清HIF-1α和VEGF水平之间,及与血清癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、细胞角蛋白（CYFRA）21-1之间无显著相关性。化疗前血清HIF-1α和VEGF含量在年龄、性别、病理类型、分期、有无胸水、疗效上无明显统计学意义。结论:检测晚期NSCLC患者外周血VEGF,可能有利于协助评估化疗疗效。     

Study on the clinical-pathological significance of microvessel density and vascular endothilial growth factor expression in primary liver cancer

Recentstudiesrevealedthattumorrecurrenceandmetastasisisassociatedwiththeintratum0ralmicrovesseldensity(MVD).TheMVD0fmanytumors(suchasbreast,st0mach,renalandcoloncancer)iscorrelatedwithpost0perativerecurrenceandmetastasis,anditisanindependentpr0gnosticindicatoL[l-]Severalangi0genicfactors,suchasbasicfibroblastgrowthfactor(BFGF),epidermalgrowthfactor(EGF),vascularendothelialgrowthfactor(VEGF)andplateletderivedgrowthfactor(PDGF)etcaresecretedbytUmorcells.VEGFisapotentangiogenicfactoLTh…     

食管癌放疗后患者血清VEGF检测预测复发价值分析

目的：探讨血清血管内皮生长因子（vascular endothelial growth factor,VEGF）水平对食管癌放疗后吞咽困难原因判断的价值。方法：新疆维吾尔自治区人民医院2009—0301—2012—12一01收治129例行根治性放疗的食管鳞状细胞癌患者,放疗后3～12个月随访,采用酶联免疫吸附法检测血清中VEGF水平,对患者吞咽功能进行Stooler分级评估,并进行血清VEGF水平与Stooler分级相关性分析,对其中25例接受胃镜和病理检查的患者,采用ROC曲线法分析VEGF水平对食管癌放疗后局部复发的诊断价值。结果：放疗后12个月内出现吞咽困难比率为41．80％;有吞咽困难患者血清VEGF平均水平为（249．81±91.64）μg／L,明显高于无吞咽困难患者（177．43±154．54）μg／L,t=3．09,P=0．003;血清VEGF水平与吞咽困难程度具有明显的相关性（spearman相关系数p=0．523,P=0．001）;血清VEGF水平对食管癌放疗后有吞咽困难者原位复发诊断的灵敏度为75．00％,特异度为69．23％,诊断界值为288．70μg／L。结论：血清VEGF水平对食管癌放疗后吞咽困难性质的判断具有一定的诊断价值,血清VEGF明显升高者肿瘤局部复发的可能性大。     

血清VEGF和Endostatin水平与消化系肿瘤临床病理特征的关系

目的〖HT5"SS〗： 探讨消化道肿瘤患者手术前后血清血管内皮生长因子（vascular endothelial growth factor,VEGF）和Endostatin的动态变化规律及其与临床病理特征的关系。〖HT5W〗方法〖HT5"SS〗： ELISA法检测胃癌、肝癌、结直肠癌患者术前及术后2周血清VEGF和Endostatin水平,并分别以慢性胃炎、慢性乙型肝炎、结肠腺瘤患者和健康人群作对照。〖HT5W〗结果〖HT5"SS〗： 胃癌、肝癌、结直肠癌患者术前血清VEGF和Endostatin水平分别显著高于慢性胃炎、慢性乙型肝炎、结肠腺瘤患者及健康人群组（P<0.01）;术前血清VEGF、Endostatin水平与细胞分化程度、肿瘤大小、浸润深度、区域淋巴结转移、远处转移及临床分期密切相关(P<0.05),与性别、肿瘤部位等因素无关(P>0.05);术后2周血清VEGF水平较术前均有显著性下降(P<0.01),而血清Endostatin水平较术前升高(P<0.01)。〖HT5W〗结论〖HT5"SS〗： 胃癌、肝癌、结直肠癌患者血清VEGF和Endostatin水平升高,且与肿瘤细胞分化程度、肿瘤大小、浸润深度、区域淋巴结转移、远处转移及临床分期密切相关,它们可推荐作为评价胃癌、肝癌、结直肠癌恶性行为、预测浸润和转移程度的有效指标。     

血清白细胞介素18在前列腺癌患者中的临床价值

Objective: To determine serum interleukin-18 (IL-18) levels and their clinical significance in patients with prostate cancer. Methods: Peripheral blood samples were obtained from 38 nonmetastatic and 18 metastatic prostate cancer patients who underwent curative surgery and from 25 healthy volunteers. The serum IL-18 level was determined in each sample with the enzyme-linked immunosorbent assay. Results: The levels of serum IL-18 were increased significantly in prostate cancer patients compared with control subjects (P ＜ 0.05). Serum IL-18 levels were significantly higher in the metastatic patients compared with the nonmetastatic patients (P ＜ 0.01). Patients with bone metastasis had higher serum IL-18 levels compared with patients with liver and lung metastasis (P ＜ 0.01). When the patients were subdivided into groups, it was found that the serum IL-18 levels in patients with T2, T3 and T4 stage were significantly higher than that of T1 stage patients (P ＜ 0.01). Patients with IL-18 levels ≥ 316 pg/mL experienced a significantly lower survival rate compared with the patients who had IL-18levels ＜ 316 pg/mL after undergoing surgery (P ＜ 0.05). The serum IL-18 level was identified as an independent postoperative prognostic factor in multivariate survival analysis using a Cox proportional hazards model (hazard ratio, 4.21; P = 0.02).Conclusion: The serum IL-18 level may be a useful marker in monitoring prostate cancer patients. IL-18 activity in prostate cancer patients with bone metastasis may be more valuable in the follow-up.     

Clinical value of serum tumor supplied group of factor in diagnosis of epithelial ovarian cancer

Tumor supplied group of factor (TSGF), whose original name was tumor specific growth factor, is a new tumor marker associated with vascular proliferation of malignant tumor. We investigated the correlation of the serum level of TSGF with VEGF and CA125 in patients with epithelial ovarian cancer and benign ovarian lesion, and compared their clinical diagnostic value for epithelial ovarian cancer. MATERIALS AND METHODS Clinical Materials During the period from Sep. 1997 to Sep…